Insights

Xcenda

The European Medicines Agency to Find a New Home After Brexit

Inverted color AmerisourceBergen icon
Xcenda
June 2018

Xcenda

Are Emerging Value Frameworks a Path to Implementing Value-Based Pricing?

Inverted color AmerisourceBergen icon
Xcenda
June 2018

Xcenda

HTA Quarterly | Summer 2018

Inverted color AmerisourceBergen icon
Xcenda
June 2018

Xcenda

Applying Cost-Effectiveness Thresholds to the Real World: Implications on Access for Medicare Beneficiaries

Inverted color AmerisourceBergen icon
Xcenda
May 2018

Xcenda

Webinar: The Emergence of Copay Accumulator Programs

Corey Ford
Corey Ford, MHA
May 2018

Xcenda

State-Led: The Push for Transparency in Drug Pricing

Inverted color AmerisourceBergen icon
Xcenda
April 2018

AmerisourceBergen

Rethink: Payer Strategies for Commercializing Cell and Gene Therapies

Inverted color AmerisourceBergen icon
AmerisourceBergen
April 2018

Insights from managed care executives on the future of coverage and outcomes evaluation.

Xcenda

Seeing the Value and Transparency of Medicare Part B

Jennifer Snow, MPH
April 2018

Xcenda

HTA Quarterly Spring 2018

Inverted color AmerisourceBergen icon
Xcenda
March 2018

Xcenda

Achieving Market Access Across the Globe for CGTs

Inverted color AmerisourceBergen icon
Xcenda
March 2018

Xcenda

Payer Tactics to Manage Commercial Copay Assistance Gaining Traction

Corey Ford
Corey Ford, MHA
March 2018

Xcenda

Implementing Coverage With Evidence Development

Inverted color AmerisourceBergen icon
Xcenda
March 2018

Xcenda

Recent Trends in Oncology Appraisal Decisions: NICE vs. SMC

Inverted color AmerisourceBergen icon
Xcenda
March 2018

Xcenda

Xcenda Examines the Impact of the Tax Cuts and Jobs Act on the Life Science Sector

Benjamin Parcher, PharmD, MS
February 2018

Xcenda

2018 Trends-Leaning Into the Chaos

Inverted color AmerisourceBergen icon
Xcenda
January 2018

Xcenda

Xcenda Collaborates with Family Reach on Critical Issue - Cancer-Related Financial Toxicity

Inverted color AmerisourceBergen icon
Xcenda
January 2018

AmerisourceBergen

What Do Payers Think About Digital Health Technologies

Inverted color AmerisourceBergen icon
AmerisourceBergen
September 2017

How are payers thinking about apps, wearables and other digital health technologies?

Xcenda

HTA Quarterly Late Summer 2017

Inverted color AmerisourceBergen icon
Xcenda
September 2017

Xcenda

Medical Nutritional Therapy: Achieving Reimbursement Across the Globe for Unique Non-drug Therapy Options

Inverted color AmerisourceBergen icon
Xcenda
September 2017

Xcenda

Brazil—The Largest Market in Latin America

Inverted color AmerisourceBergen icon
Xcenda
September 2017

Xcenda

Biologic Treatments for Severe Asthma—a Paradigm Shift From Targeted to More Personalized Medicine

Inverted color AmerisourceBergen icon
Xcenda
September 2017

Xcenda

HTA Quarterly | Summer 2017

Inverted color AmerisourceBergen icon
Xcenda
August 2017

Xcenda

Finding the Balance in Pharmaceutical Evidence Exchange With Payers and Providers

Jennifer Snow, MPH
August 2017

Xcenda

Hearing the Patient Voice: How 4 Countries are Utilizing Patient Input

Inverted color AmerisourceBergen icon
Xcenda
August 2017

Xcenda

Understanding the Columbian Health Care Market

Inverted color AmerisourceBergen icon
Xcenda
August 2017

Xcenda

HTAQ Summer 2017 Duchenne Muscular Dystrophy New and Revitalized Drugs Bring Hope to Patients

Inverted color AmerisourceBergen icon
Xcenda
August 2017

Xcenda

Biosimilar Coding—Could There Be Billions in Hidden Savings?

Amanda Forys, MSPH
August 2017

Xcenda

Commercializing Cell and Gene Therapies

Inverted color AmerisourceBergen icon
Xcenda
June 2017

Xcenda

Payer Perceptions and Utilization of ICER Value Assessment Framework

Inverted color AmerisourceBergen icon
Xcenda
June 2017

Xcenda

FDAMA 114 and the 21st Century Cures Act

Inverted color AmerisourceBergen icon
Xcenda
May 2017

Xcenda

Xcenda Conducts Unique Research on Air Medical Services Costs

Inverted color AmerisourceBergen icon
Xcenda
March 2017

Xcenda

Analyzing the impact of Medicare Part D for Oncology Patients

Inverted color AmerisourceBergen icon
Xcenda
June 2016

Xcenda

Part B Drug Payment Change: Understanding the Implications for Pharma

Amanda Forys, MSPH
March 2016

Xcenda

Oncology in the Era of Value Frameworks: Perspectives Payers Oncologists Product Planning

Inverted color AmerisourceBergen icon
Xcenda
December 2015